List of Tekturna Hct drug patents
Tekturna Hct is owned by Noden Pharma.
Tekturna Hct contains Aliskiren Hemifumarate; Hydrochlorothiazide.
Tekturna Hct has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Tekturna Hct are:
- US9023893
Tekturna Hct was authorised for market use on 18 January, 2008.
Tekturna Hct is available in tablet;oral dosage forms.
The generics of Tekturna Hct are possible to be released after 13 July, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9023893 | NODEN PHARMA | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
Mar, 2022
(1 year, 17 days ago) | |
| US8618172 | NODEN PHARMA | Galenical formulations of organic compounds |
Jul, 2028
(5 years from now) | |
Drugs and Companies using ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE ingredient
Market Authorisation Date: 18 January, 2008
Treatment: NA
Dosage: TABLET;ORAL
TEKTURNA HCT family patents
12
European Union
7
New Zealand
7
Korea, Republic of
7
Japan
6
United States
5
Spain
5
China
3
Portugal
3
Germany
3
Russia
3
Norway
3
Hong Kong
3
Canada
3
Slovenia
3
Israel
3
Poland
3
Australia
3
Denmark
2
United Kingdom
2
Brazil
2
Mexico
2
Austria
2
Peru
2
South Africa
2
Luxembourg
2
Hungary
2
Czech Republic
2
Ecuador
2
Netherlands
1
Singapore
1
Malaysia
1
Guatemala
1
Argentina
1
Morocco
1
Taiwan, Province of China
1
Tunisia
1
Slovakia
1
Cyprus
1
Chile
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic